The goal of this clinical trial is to compare two different skin incisions used in surgery to treat trigger finger in adult patients. Trigger finger occurs when a finger gets stuck or locks because of swelling of the sheath around the tendons the help move the fingers. The main questions it aims to answer are (1) Does the type of skin cut affect how well the hand works 6 weeks after surgery? (2) Does the type of skin cut affect pain levels, scar healing, and how quickly people return to their normal activities? Orthopaedic surgeons will compare a straight incision along the finger (longitudinal incision) to a incision across the crease in the palm (transverse incision) to see if one type of incision results in better recovery, less pain, a better scar, and higher patient satisfaction with the procedure. Participants who have trigger finger and are indicated for surgery will have surgery to release the pulley in their finger using one of the two types of incisions (assigned by chance). Participants will fill out questionnaires about their hand function and pain before surgery and at follow-up visits. Participants will have their scar checked and rated at about 2, 6, and 12 weeks after surgery, and report on their pain for the first few days after surgery and when they can return to work and move their finger without pain.
This is a prospective, multicenter, randomized controlled trial comparing clinical and patient-reported outcomes between longitudinal and transverse incisions for open A1 pulley release in the treatment of idiopathic trigger finger (stenosing tenosynovitis of the fingers, excluding the thumb). Stenosing tenosynovitis of the flexor tendon, commonly known as trigger finger, is a frequent hand condition with a lifetime incidence of approximately 2.6%. It results from inflammation and a size mismatch between the flexor tendon and the first annular (A1) pulley, leading to painful catching, clicking, or locking during finger flexion and extension. When conservative measures such as splinting and corticosteroid injections fail, surgical release of the A1 pulley is indicated. Although A1 pulley release is one of the most commonly performed hand procedures and is generally considered safe and effective, reported complication rates range from 6% to 36% and include wound-healing issues, persistent or recurrent triggering, infection, wound dehiscence, and painful scar formation. Patient dissatisfaction is most often related to scar tenderness, irritation, and cosmetic concerns that can limit tendon gliding and hand function. Two incision techniques are commonly used: longitudinal (along the axis of the finger) and transverse/oblique (within the distal palmar crease). Proponents of the longitudinal incision emphasize improved visualization and extensibility, while proponents of the transverse incision highlight superior cosmesis and faster healing. Despite the frequency of this procedure, high-quality evidence comparing these approaches remains limited. This trial was designed to address this knowledge gap in a setting of clinical equipoise, where surgeons at the participating centers routinely use both techniques. The primary objective is to compare post-operative upper-extremity function, as measured by the PROMIS Upper Extremity (UE) score at approximately 6 weeks, between the longitudinal and transverse incision groups. Secondary objectives include comparing post-operative pain (Numeric Pain Scale), time to return to work, time to pain-free finger extension (tabletop test), additional PROMIS domains (Physical Function, Pain Interference, and Depression), scar outcomes using validated scales (POSAS, SCAR-Q, and 0-10 global satisfaction), and complication rates (wound dehiscence, infection, return to OR, and revision surgery). This investigator-initiated, multicenter, 1:1 randomized controlled trial will enroll approximately 200 participants across participating sites, with Washington University School of Medicine/Barnes-Jewish Hospital system serving as the lead site and the University of Chicago as a second site. Block randomization, stratified by site, will be performed immediately after consent using a secure web-based randomization system. Eligible participants are adults ≥18 years old with a diagnosis of trigger finger (fingers only) who provide written informed consent; exclusion criteria include revision surgery, prior surgery on the affected finger, or refusal of consent. The intervention consists of standard open A1 pulley release performed through either a longitudinal incision or a transverse incision placed in the distal palmar crease, with all other aspects of surgical technique and post-operative care standardized. Intra-operative data collected will include the need for FDS excision and any incision extension. The primary outcome is the PROMIS Upper Extremity score at \~6 weeks post-operatively. Secondary outcomes include Numeric Pain Scale scores (days 1-3, \~2 weeks, \~6 weeks, and \~12 weeks), days to return to work, days to pain-free finger extension (tabletop test), PROMIS Physical Function, Pain Interference, and Depression scores, scar metrics (POSAS, SCAR-Q, and 0-10 global satisfaction) at \~2, \~6, and \~12 weeks, and complication rates. Study procedures include pre-operative collection of demographics, medical history (including diabetes, depression/anxiety, and chronic opioid use), trigger finger details, and baseline PROMIS scores. Post-operatively, pain reports will be collected on days 1-3, with in-person or virtual assessments at \~2 weeks, \~6 weeks (primary endpoint), and \~12 weeks; scar photographs will be obtained during in-person visits. All data will be entered into a Washington University REDCap instance. Continuous outcomes will be compared using t-tests or Mann-Whitney U tests, while categorical outcomes will use chi-square or Fisher's exact tests; mixed-effects models will account for repeated measures and site effects. The sample size was calculated to detect a 4-point difference in PROMIS UE score (minimal clinically important difference) with 80% power and α=0.05, accounting for the reported standard deviation. The results of this trial will provide evidence-based guidance on optimal incision selection to improve functional recovery, reduce pain, optimize scar healing, and enhance patient satisfaction after A1 pulley release.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Surgical release of the first annular (A1) pulley to treat stenosing tenosynovitis (trigger finger). Participants receive either a longitudinal or transverse incision based on their randomized arm assignment. All other aspects of surgical technique and post-operative care are standardized.
The University of Chicago Medicine
Chicago, Illinois, United States
RECRUITINGWashington University and Barnes-Jewish Orthopedic Center
St Louis, Missouri, United States
RECRUITINGPROMIS Upper Extremity Score
Patient-reported upper extremity function measured by the PROMIS Upper Extremity (UE) scale (range: 0-100, where higher scores indicate better upper extremity function).
Time frame: Approximately 6 weeks post-operatively
Numeric Pain Scale (NPS)
Self-reported pain intensity measured by the Numeric Pain Scale (range: 0-10, where 0 = no pain and 10 = worst possible pain; higher scores indicate worse pain).
Time frame: Days 1-3, approximately 2 weeks, 6 weeks, and 12 weeks post-operatively
Days to Return to Work
Number of days from surgery until the patient returns to work (or usual activities if retired/unemployed).
Time frame: Up to 12 weeks post-operatively
Time to Pain-Free Finger Extension (Tabletop Test)
Number of days from surgery until the patient achieves pain-free finger extension, assessed by the tabletop test. This is a binary test (yes/no) which assesses if the patient can lay their hand flat on a tabletop without any residual triggering.
Time frame: Up to 12 weeks post-operatively
PROMIS Physical Function Score
Patient-reported physical function measured by the PROMIS Physical Function scale (range: 0-100, where higher scores indicate better physical function).
Time frame: Approximately 6 weeks and 12 weeks post-operatively
PROMIS Pain Interference Score
Patient-reported pain interference measured by the PROMIS Pain Interference scale (range: 0-100, where higher scores indicate greater pain interference / worse outcome).
Time frame: Approximately 6 weeks and 12 weeks post-operatively
PROMIS Depression Score
Patient-reported depressive symptoms measured by the PROMIS Depression scale (range: 0-100, where higher scores indicate more depressive symptoms / worse outcome).
Time frame: Approximately 6 weeks and 12 weeks post-operatively
Patient and Observer Scar Assessment Scale (POSAS)
Scar quality assessed by the Patient and Observer Scar Assessment Scale (POSAS; total score range 6-60 per scale, where higher scores indicate worse scar appearance and symptoms).
Time frame: Approximately 2 weeks, 6 weeks, and 12 weeks post-operatively
SCAR-Q Score
Patient-reported scar outcome measured by the SCAR-Q (higher scores indicate better scar outcome).
Time frame: Approximately 2 weeks, 6 weeks, and 12 weeks post-operatively
Global Satisfaction with Scar
Patient global satisfaction with scar appearance and symptoms measured on a numeric rating scale (range: 0-10, where 0 indicates completely dissatisfied and 10 indicates completely satisfied; higher scores indicate better outcome).
Time frame: Approximately 2 weeks, 6 weeks, and 12 weeks post-operatively
Complication Rate
Rate of post-operative complications including wound dehiscence, infection, return to the operating room, and need for revision surgery (reported as the proportion of patients experiencing each event).
Time frame: Up to 12 weeks post-operatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.